US Patent

US9597402 — Sustained release small molecule drug formulation

Formulation · Assigned to Durect Corp · Expires 2026-09-26 · 0y remaining

Vulnerability score 43/100 Strong — defensible against typical IPR challenges

What this patent protects

This patent protects a sustained release injectable depot formulation that incorporates a small molecule drug, such as Risperdal, in a biocompatible polymer gel.

USPTO Abstract

An injectable depot formulation includes a biocompatible polymer, an organic solvent combined with the biocompatible polymer to form a viscous gel, and a small molecule drug incorporated in the viscous gel such that the formulation exhibits an in vivo release profile having C max to C min ratio less than 200 and lag time less than 0.2.

Drugs covered by this patent

Patent Metadata

Patent number
US9597402
Jurisdiction
US
Classification
Formulation
Expires
2026-09-26
Drug substance claim
No
Drug product claim
Yes
Assignee
Durect Corp
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.